ArriVent Biopharma

Historical price data

ArriVent Biopharma is a clinical-stage oncology company with a mission to identify, develop, and commercialize differentiated medicines from global innovation centers. Its core strategy, 'R&D Done Differently,' focuses on in-licensing high-potential, late-preclinical or early-clinical assets from partners in regions like China and South Korea, then leveraging its veteran team's expertise to rapidly advance them through global development and regulatory approval. Key achievements include initiating a pivotal Phase 3 trial for its lead asset, firmonertinib, in EGFR-mutant NSCLC, securing FDA Breakthrough Therapy Designation, and building a preclinical pipeline of novel antibody-drug conjugates (ADCs).

ArriVent's core 'platform' is its strategic 'R&D Done Differently' operating model, which focuses on identifying, in-licensing, and accelerating the global development of innovative oncology therapeutics sourced from emerging biopharma hubs like China and South Korea.